Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial-Reference-Cited by-同舟云学术

Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial

Published:2021-10 Issue:10 Volume:6 Page:816-825
ISSN:2468-1253
Container-title:The Lancet Gastroenterology & Hepatology
language:en
Short-container-title:The Lancet Gastroenterology & Hepatology

Author:

Hanauer Stephen,Liedert Bernd,Balser Sigrid,Brockstedt Ekkehard,Moschetti Viktoria,Schreiber Stefan

Funder

Boehringer Ingelheim

Boehringer Ingelheim International GmbH

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference33 articles.

1. Crohn's disease;Baumgart;Lancet,2012

2. Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies;Ng;Lancet,2017

3. The cost of inflammatory bowel disease: an initiative from the Crohn's & Colitis Foundation;Park;Inflamm Bowel Dis,2020

4. Anti-TNF therapy in Crohn's disease;Adegbola;Int J Mol Sci,2018

5. Anti-TNF-α therapies for the treatment of Crohn's disease: the past, present and future;Berns;Expert Opin Investig Drugs,2016

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical experience of using biosimilars in Crohn’s disease and their effectiveness;Expert Opinion on Biological Therapy;2024-09-13

2. Anti-TNFα in inflammatory bowel disease: from originators to biosimilars;Frontiers in Pharmacology;2024-07-24

3. Relative bioavailability, immunogenicity, and safety of two adalimumab-adbm formulations in healthy volunteers: a double-blind, randomized, single-dose, parallel-arm Phase I trial (VOLTAIRE-HCLF);Expert Opinion on Biological Therapy;2024-05-19

4. Consistent efficacy outcomes between phase 2 and phase 3 trials in Crohn’s disease or ulcerative colitis in adults: a meta-analysis;Inflammation Research;2024-04-08

5. Biosimilars in IBD: What Every Clinician Needs to Know;Current Gastroenterology Reports;2024-01-20